Olaratumab在治疗晚期软组织肉瘤的研究现状

Current situation of olaratumab for the treatment of advanced soft tissue sarcoma

Olaratumab是一种重组人源免疫球蛋白G1(IgG1)单克隆抗体,可特异性结合并阻断血小板衍生生长因子受体α(PDGFRα),抑制PDGFRα促进肿瘤和基质细胞(包括肉瘤)增殖、转移并维持肿瘤微环境的作用。2016-10-19,美国食品药品监督管理局(FDA)批准olaratumab联合多柔比星用于不适合根治性放射治疗或手术、但适合蒽环类治疗的成人晚期软组织肉瘤(STS)组织学亚型,是首个被批准用于治疗STS的单克隆抗体。本文对olaratumab的作用机制、药代动力学、临床应用和安全性方面做一综述。

Olaratumab,a recombinant human immunoglobulin G subclass 1 （IgG1） monoclonal blocking antibody that binds specifically to human platelet -derived growth factor receptor alpha （PDGFRot） , plays an im- portant role in inhibition of PDGFR（x - induced cancer cell prolifera- tion, metastasis, and maintenance of the tumor microenvironment. On October 19th, 2016 Food and Drug Adminstration （FDA） approved olaratumab as the first monoclonal antibody, in combination with doxoru- bicin, for the treatment of adult patients with soft tissue sarcoma （STS） with a histologic subtype which can be treated by anthracycline - contai- ning regimen without radiotherapy or surgery. In this article, the mecha- nism, pharmacokinetics, clinical application and adverse reactions of olaratumab were reviewed.